| INTRODUCTION
The incidence of patients with gastric cancer has gradually decreased over recent decades. 1 Gastric cancer represents the third-and fifth-leading cause of cancer death in male and female individuals, respectively, worldwide. 1 This indicates that patients with unresectable advanced and recurrent gastric cancer have poor prognosis despite recent advances in chemotherapeutic treatments, including the introduction of novel molecularly targeted drugs such as trastuzumab and ramucirumab. 2 Novel therapeutic strategies based on new antitumor agents are thus important for patients with advanced gastric cancer.
Immune checkpoint blockade has gained attention as a new molecularly targeted therapy in patients with various malignancies, including gastric cancer. 3, 4 Surprisingly, immune checkpoint inhibitor therapy appears to offer the clinical potential to control tumor growth and distant metastasis. 3, 4 According to a phase III controlled study of nivolumab, an anti-programmed cell death protein 1 (PD-1)
antibody, in previously untreated patients with advanced melanoma, 1-year overall survival rates were 72.9% and 42.1% in the nivolumab and dacarbazine groups, respectively. 5 In addition, objective response rates were 40.0% and 13.9% in the nivolumab and dacarbazine groups, respectively. 5 Accordingly, that CheckMate-066 clinical trial reported the clinical utility of immune checkpoint blockade as a promising antitumor agent in patients with metastatic melanoma.
Programmed cell death protein-1 and programmed death-ligand 1 (PD-L1) are representative immune checkpoint molecules and the PD-1/PD-L1 signaling pathway plays a principal role in the inhibition of T cell-mediated immune response. [6] [7] [8] To date, immunohistochemical analyses have indicated that PD-L1 is overexpressed in tumor cells with melanoma, non-smallcell lung cancer, renal cell carcinoma, and gastric cancer. [9] [10] [11] [12] Recent studies have shown a close relationship between PD-L1 expression in primary tumor cells of several malignancies and wellknown prognostic clinicopathological factors, such as depth of tumor invasion, lymph node metastasis, distant metastasis, and stage. [9] [10] [11] [12] However, the clinical significance of PD-L1 expression in blood specimens of patients with gastric cancer has not yet been assessed. Naturally, non-invasive liquid biopsy using blood specimens has the clinical attractiveness of being a simple and repeatable sampling tool. 13 The aim of this study was to investigate PD-L1 expression in blood specimens and to assess the relationships between PD-L1 expression and clinicopathological features, including prognosis, in patients with gastric cancer.
| MATERIALS AND METHODS

| Gastric cancer cell lines
Three gastric cancer cell lines (MKN-7, MKN-74, and NCI-N87) were cultured in RPMI-1640 (Nissui Pharmaceutical, Tokyo, Japan) supplemented with 10% FCS (Mitsubishi Kasei, Tokyo, Japan), 100 U/mL penicillin, and 100 U/mL streptomycin. All cell lines were incubated at 37°C in a humidified atmosphere containing 5% CO 2 , then assessed by immunocytochemistry and RT-PCR. 2.4 | Blood processing and RNA extraction for RT-
| Patients
PCR assay
Blood (5 mL) was withdrawn from each patient into tubes containing sodium citrate before treatment. Blood specimens were processed within 30 minutes after drawing. Blood cells were then collected using lymphocyte separation buffer (Gentra Systems, Minneapolis, MN, USA). All blood and cell lines were mixed with 1 mL Isogen (Nippon Gene, Toyama, Japan) and immediately cryopreserved at À80°C until RNA extraction. Total RNA was isolated and purified using phenol-chloroform, as previously described. 15 The concentration and purity of total RNA were examined using a NanoDrop Lite spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA). 
| Quantitative RT-PCR assay
All total RNA samples were reverse transcribed using the Advantage RT-for-PCR kit (Takara Bio USA, Terra Bella, CA, USA), as previously described. were calculated based on standard curves with four serial dilutions of plasmid templates. Programmed death-ligand 1 mRNA copy numbers were normalized by GAPDH mRNA copy numbers (relative PD-L1 mRNA copies: absolute PD-L1 mRNA copies / absolute GAPDH mRNA copies).
| Statistical analysis
Differences in PD-L1 mRNA expression between blood specimens from patients with early gastric cancer and from those with advanced gastric cancer were assessed using the Wilcoxon rank-sum test. Receiver operating characteristic (ROC) curves were constructed, then the area under the curve was calculated to evaluate the predictive ability of PD-L1 mRNA expression for distinguishing patients with and without distant metastasis. The relationship between the status of PD-L1 expression and categorical clinicopathological features was statistically analyzed using the chisquared-test and Fisher's exact tests. Survival curves were generated using the Kaplan-Meier method and differences in survival were examined by the log-rank test. Figure 2) . Accordingly, the relative number of PD-L1 mRNA copies was significantly lower in patients with early gastric cancer than in advanced gastric cancer (P = .002).
| Relationship between PD-L1 expression and clinicopathological features
To assess the relationship between the status of PD-L1 mRNA expression and clinicopathological factors, we divided all patients into groups with high (n = 62) and low expression (n = 62) based on the median relative number of PD-L1 mRNA copies. This binary classification for PD-L1 mRNA expression was used in subsequent analyses.
The status of PD-L1 expression correlated significantly with depth of tumor invasion, distant metastasis, and UICC stage (P = .001, P < .001, and P < .001, respectively) ( Table 1 ). According to the ROC analysis, the area under the curve for detecting patients with distant metastasis was 0.772 ( Figure 3) . The sensitivity and specificity of PD-L1 mRNA expression for detecting patients with distant metastasis were 0.814 and 0.667, respectively.
| Relationship between PD-L1 expression and prognosis
The 5-year survival rate was significantly lower in patients with high PD-L1 expression than in those with low PD-L1 expression (50.0%
vs 84.1%, P < .0001; Figure 4 ).
| Univariate and multivariate analyses of survival
Univariate analysis revealed that the depth of tumor invasion, lymph node metastasis, distant metastasis, serum CEA level, serum CA19-9 level, and PD-L1 expression correlated significantly with postoperative survival (P < .0001 each) ( Table 2) . Moreover, multivariate analysis selected distant metastasis, serum CEA level, and PD-L1 expression as independent prognostic factors (P < .0001, P = .020, and P = .024, respectively) ( Table 2 ).
| DISCUSSION
The present study examined PD-L1 mRNA expression by qRT-PCR assay in peripheral blood specimens from patients with early and advanced gastric cancer. We also investigated the relationship between PD-L1 mRNA expression and tumor properties to assess the clinical impact of expression in patients with gastric cancer. According to a previously published report, PD-L1 is expressed on antigen-presenting cells and tumor cells. 8 We initially investigated PD-L1 protein expression using immunocytochemistry in gastric cancer cell lines. This immunocytochemical analysis showed CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; T1, invasion of lamina propria or submucosa; T2, invasion of muscularis propria; T3, invasion of subserosa; T4, penetration of serosa or invasion of adjacent structures.
F I G U R E 3
Receiver operating characteristic curve for discriminating gastric cancer patients with and without distant metastasis based on programmed death-ligand 1 mRNA expression. Area under the curve was 0.772 To date, several investigators have assessed the prognostic significance of PD-L1 expression in primary tumor sites of various malignancies, including gastric cancer. [9] [10] [11] [12] According to the majority of these reports based on immunohistochemical analyses, patients with high PD-L1 expression displayed significantly poorer prognosis than those with low PD-L1 expression. [9] [10] [11] [12] In the present study,
qRT-PCR analysis of blood specimens showed significantly worse prognosis in patients with high PD-L1 mRNA expression than in those with low PD-L1 mRNA expression (P < .0001). randomized controlled trial comparing pembrolizumab and docetaxel for previously treated, PD-L1-positive, advanced non-smallcell lung cancer, a subgroup analysis of progression-free survival revealed the clinical utility of PD-L1 tumor proportion score for predicting responders to pembrolizumab. 21 The KEYNOTE-010 study proposed the status of PD-L1 expression as a useful biomarker to discriminate responders from non-responders in PD-1/ PD-L1 immunotherapy. 21 However, heterogeneous expression of PD-L1 within primary tumor sites is one of the key issues in the clinical management of PD-1/PD-L1 checkpoint blockades. 22 
